Can a simple supplement protect your heart? new trial investigates
NCT ID NCT05689710
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a daily supplement containing inositol and alpha-lactalbumin can improve blood sugar, cholesterol, blood pressure, and heart health in people with metabolic syndrome who are at risk for cardiac fibrosis. Thirty participants will take the supplement for 180 days. The goal is to see if this simple approach can help control the condition and prevent heart damage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
inositol and alpha-lactalbumin (dietary supplement)
What this could lead to
If it works, this could point toward a simple dietary supplement to help manage metabolic syndrome and reduce the risk of heart damage.
What could go wrong
This is a small, early-stage trial with only 30 participants, and it is currently suspended. The supplement may not produce meaningful improvements, and results may not apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UOC Medicina Interna e Nefrologia P.O. AQ
L’Aquila, Italy